Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Tissue Cell ; 82: 102092, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37075679

RESUMO

Mesenchymal stem cells (MSCs) are being used in clinical trials given their proliferative potential, immunomodulatory effects, and their pro-angiogenic, anti-apoptotic, and anti-fibrotic properties. Umbilical cord tissue is an excellent source of MSCs. Iron-fortified calf serum is being used to culture MSCs as an alternative to fetal bovine serum since it is relatively inexpensive. Fetal calf serum is fortified with iron since calves are often fed a low-iron diet. However, the use of iron-fortified calf serum is still problematic since it is xenogeneic. Lately, human platelet lysate is being used for the culture of human cells. To increase its shelf life, human platelet lysate was lyophilized and used for culturing human umbilical cord tissue mesenchymal stem cells (hUCT-MSCs). This study compares the culture of hUCT-MSCs with either iron-fortified calf serum or lyophilized human platelet lysate (LHPL). Trilineage differentiation potential (for chondrogenesis, adipogenesis, or osteogenesis) was assessed and immunomodulatory properties of hUCT-MSC were studied using the Mixed Lymphocyte Reaction (MLR) to detect inhibition of the proliferation of lymphocytes. This study concludes the potency of LHPL as the best alternative to Iron-Fortified Calf Serum (IFCS) for culture expansion of hUCT-MSC. hUCT-MSC cultured with LHPL display characteristic surface markers and have the capacity for trilineage differentiation.


Assuntos
Técnicas de Cultura de Células , Células-Tronco Mesenquimais , Humanos , Animais , Bovinos , Proliferação de Células , Diferenciação Celular , Cordão Umbilical , Suplementos Nutricionais , Células Cultivadas
2.
J Family Med Prim Care ; 11(7): 3891-3900, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-36387645

RESUMO

Background: SARS-CoV-19 or popularly known as COVID-19 is recognized as a global public health emergency and a pandemic necessitating readiness of the health system and its operational work force to address the unprecedent challenge. Objective: To assess perceived stress and coping methods using novel brief COPE-4 factor structure and narrate thematic testimonials among health care professionals involved in COVID care in India. Settings and Designs: Health care settings and multi-state cross-sectional study. Methods and Material: A cross sectional mixed-methods study, with multi-modal aids was undertaken during April-May, 2020 using a novel brief COPE-4 Factor structure. Oral informed consent was obtained to document narrative testimonials verbatim from interviews among doctors, nurse practitioners. Statistical Analysis Used: The web-survey data from Google forms analyzed using STATA (Ver 12.0) statistical package. The interview content was subjected to manual inductive thematic coding, grouped into piles to identify broad themes as main categories. Results: Among total 218 respondents, 75 (34.4%) were female and 143 (65.6%) male, mean age of 34.71 (SD = 8.9) years. Majority of the respondents were medical post-graduates on duty (38%) followed by nurses (25%) and public health professionals (14%). Slightly higher levels of stress seen among respondents involved in COVID-19 duty, compared to those not involved (p < 0.001) and positive thinking is the major coping method adopted. Conclusions: Appraising the coping mechanisms of health care professionals reveals positive outlook amidst medium levels of perceived stress while providing COVID-19 pandemic related health care services.

3.
Artigo em Inglês | MEDLINE | ID: mdl-35356240

RESUMO

Aldose reductase (ALR2) activation in the polyol pathway has been implicated as the primary mechanism for the progression of diabetic retinopathy. Most of the aldose reductase inhibitors (ARIs), used for the treatment of diabetic complications, were withdrawn due to ineffective treatment and adverse side effects caused by nonspecificity. Epalrestat, a carboxylic acid inhibitor, is the only ARI used for the treatment of diabetic neuropathy, though associated with minor side effects to 8% of the treated population. Our study exploited the interactions of Epalrestat-ALR2 crystal structure for the identification of specific phytocompounds that could inhibit human lens ALR2. 3D structures of plant compounds possessing antidiabetic property were retrieved from PubChem database for inhibition analysis, against human lens ALR2. Among the shortlisted compounds, Agnuside and Eupalitin-3-O-galactoside inhibited lens ALR2 with IC50 values of 22.4 nM and 27.3 nM, respectively, compared to the drug Epalrestat (98 nM), indicating high potency of these compounds as ALR2 inhibitors. IC50 concentration of the identified ARIs was validated in vitro using ARPE-19 cells. The in silico and in vitro approaches employed to identify and validate specific and potent ALR2 inhibitors resulted in the identification of phytocompounds with potency equal to or better than the ALR2 inhibiting drug, Epalrestat.

4.
Front Endocrinol (Lausanne) ; 13: 1074568, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36714604

RESUMO

Wound healing is a programmed process of continuous events which is impaired in the case of diabetic patients. This impaired process of healing in diabetics leads to amputation, longer hospitalisation, immobilisation, low self-esteem, and mortality in some patients. This problem has paved the way for several innovative strategies like the use of nanotechnology for the treatment of wounds in diabetic patients. The use of biomaterials, nanomaterials have advanced approaches in tissue engineering by designing multi-functional nanocomposite scaffolds. Stimuli-responsive scaffolds that interact with the wound microenvironment and controlled release of bioactive molecules have helped in overcoming barriers in healing. The use of different types of nanocomposite scaffolds for faster healing of diabetic wounds is constantly being studied. Nanocomposites have helped in addressing specific issues with respect to healing and improving angiogenesis. Method: A literature search was followed to retrieve the articles on strategies for wound healing in diabetes across several databases like PubMed, EMBASE, Scopus and Cochrane database. The search was performed in May 2022 by two researchers independently. They keywords used were "diabetic wounds, nanotechnology, nanocomposites, nanoparticles, chronic diabetic wounds, diabetic foot ulcer, hydrogel". Exclusion criteria included insulin resistance, burn wound, dressing material.


Assuntos
Diabetes Mellitus , Pé Diabético , Nanocompostos , Nanopartículas , Humanos , Cicatrização , Bandagens , Pé Diabético/terapia , Diabetes Mellitus/terapia
5.
Biomed Pharmacother ; 109: 708-715, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30551523

RESUMO

Hyperglycemia invoke number of pathways resulting in development of diabetic retinopathy (DR), including protein kinase C activation, increased expression of VEGF, advanced glycation end product (AGEs) formation and activation of polyol pathway, among which the pathophysiology of aldose reductase (ALR2) of the polyol pathway is evident by more than a decade of research. Subtle involvement of ALR2 in invoking various pathways of diabetic complications has caused an increase in attention towards the identification of novel aldose reductase inhibitors (ARIs). Numerous ARIs of different classes were employed in the treatment of diabetic complications initially, but few came into light as drugs. Though no ALR2 inhibitor has been used for the treatment or control of DR, Epalrestat has been used worldwide for treating diabetic neuropathy. This review critically analyses different treatments available for diabetic retinopathy, their limitations and the importance of the development of novel inhibitors of ALR2 that could prevent progression of DR, by causing a direct or indirect effect on controlling factors associated with DR.


Assuntos
Retinopatia Diabética/tratamento farmacológico , Retinopatia Diabética/metabolismo , Sistemas de Liberação de Medicamentos/métodos , Aldeído Redutase/antagonistas & inibidores , Aldeído Redutase/metabolismo , Animais , Sistemas de Liberação de Medicamentos/tendências , Inibidores Enzimáticos/administração & dosagem , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , PPAR gama/agonistas , PPAR gama/metabolismo , Inibidores de Proteínas Quinases/administração & dosagem , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...